IRF7 and IFIT2 in mediating different hemorrhage outcomes for non-small cell lung cancer after bevacizumab treatment

BACKGROUND: Lung cancer has some of the highest morbidity and mortality worldwide among cancers, with non-small cell lung cancer (NSCLC) accounting for 85% of lung cancer diagnoses. Severe pulmonary hemorrhage (PH) is a serious potential adverse event in the treatment of lung cancer with bevacizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Liuying, Yin, Yuan, Qian, Danqi, Cao, Yulin, Wang, Duo, Wu, Xiaohan, Ming, Liang, Huang, Zhaohui, Zhou, Leyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183489/
https://www.ncbi.nlm.nih.gov/pubmed/37197507
http://dx.doi.org/10.21037/jtd-23-389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183489/
https://www.ncbi.nlm.nih.gov/pubmed/37197507
http://dx.doi.org/10.21037/jtd-23-389

Ejemplares similares